Clotting Factors, Coagulant Blood Products & Other Hemostatics

Policy Number: 2023D0047AG
Effective Date: October 1, 2023

Related Commercial Policy
- Home Health, Skilled, and Custodial Care Services (for Commercial Only)

Coverage Rationale

This policy refers to the following products: 1, 18, 20, 30-34, 36, 38, 39-46, 51

<table>
<thead>
<tr>
<th>Product</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor VIIa (recombinant)</td>
<td>NovoSeven® RT [coagulation factor VIIa (recombinant)] Sevenfact® [coagulation factor VIIa (recombinant)-jncw]</td>
</tr>
<tr>
<td>Factor XIII (plasma-derived)</td>
<td>Corifact® [factor XIII concentrate (human)]</td>
</tr>
<tr>
<td>Factor VIII (plasma-derived)</td>
<td>HemoM M® [antihemophilic factor (human)] Koāte®-DVI [antihemophilic factor (human)]</td>
</tr>
<tr>
<td>Factor VIII (plasma-derived) / von Willebrand Factor Complex (plasma-derived)</td>
<td>Alphanate® [antihemophilic factor (human)] Humate-P® [antihemophilic factor (human)] Wilate® [antihemophilic factor (human)]</td>
</tr>
<tr>
<td>Factor VIII (recombinant)</td>
<td>Advate® [antihemophilic factor (recombinant)] Helixate® FS [antihemophilic factor (recombinant)] Kogenate® FS [antihemophilic factor (recombinant)] Kovaltry® [antihemophilic factor (recombinant)] Novoeight® [antihemophilic factor (recombinant)] Nuwiq® [antihemophilic factor (recombinant)] Recombinate® [antihemophilic factor (recombinant)] Xyntha® [antihemophilic factor (recombinant)] Xyntha® Solofuse™ [antihemophilic factor (recombinant)]</td>
</tr>
</tbody>
</table>

Instructions for Use

See Benefit Considerations
<table>
<thead>
<tr>
<th>Product</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor IX (plasma-derived)</td>
<td>AlphaNine® SD [coagulation factor IX (human)]</td>
</tr>
<tr>
<td></td>
<td>Mononine® [coagulation factor IX (human)]</td>
</tr>
<tr>
<td></td>
<td>Profilnine SD® [factor IX complex human]</td>
</tr>
<tr>
<td>Factor IX (recombinant)</td>
<td>BeneFIX® [coagulation factor IX (recombinant)]</td>
</tr>
<tr>
<td></td>
<td>Ixinity® [coagulation factor IX (recombinant)]</td>
</tr>
<tr>
<td></td>
<td>Rixubis® [coagulation factor IX (recombinant)]</td>
</tr>
<tr>
<td>Factor IX (recombinant), long-acting</td>
<td>Alprolix® [coagulation factor IX (recombinant), Fc fusion protein]</td>
</tr>
<tr>
<td></td>
<td>Idelvion® [coagulation factor IX (recombinant), albumin fusion protein]</td>
</tr>
<tr>
<td></td>
<td>Rebinyn® [coagulation factor IX (recombinant), GlycoPEGylated]</td>
</tr>
<tr>
<td>Anti-Inhibitor Coagulant Complex (plasma-derived)</td>
<td>FEIBA® [anti-inhibitor coagulant complex (human)]</td>
</tr>
<tr>
<td>Fibrinogen Concentrate (plasma-derived)</td>
<td>RiaSTAP® [fibrinogen concentrate (human)]</td>
</tr>
<tr>
<td></td>
<td>Fibryga® [fibrinogen (human)]</td>
</tr>
<tr>
<td>Factor XIII A-subunit (recombinant)</td>
<td>Tretten® [coagulation factor XIII A-subunit (recombinant)]</td>
</tr>
<tr>
<td>Factor VIII (recombinant), long-acting</td>
<td>Adynovate® [antihemophilic factor (recombinant), PEGylated]</td>
</tr>
<tr>
<td></td>
<td>Afstyla® [antihemophilic factor (recombinant)]</td>
</tr>
<tr>
<td></td>
<td>Altuviiio™ [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehlt]</td>
</tr>
<tr>
<td></td>
<td>Eloctate® [antihemophilic factor (recombinant), Fc fusion protein]</td>
</tr>
<tr>
<td></td>
<td>Esperoct® [antihemophilic factor (recombinant), glycopegylated-eei]</td>
</tr>
<tr>
<td></td>
<td>Jivi® [antihemophilic factor (recombinant), PEGylated-aucl]</td>
</tr>
<tr>
<td>Factor VIII (recombinant), porcine sequence</td>
<td>Obizur® [antihemophilic factor (recombinant), porcine sequence]</td>
</tr>
<tr>
<td>Factor X (plasma-derived)</td>
<td>Coagadex® [coagulation factor X (human)]</td>
</tr>
<tr>
<td>Von Willebrand Factor (recombinant)</td>
<td>Vonvendi® [von Willebrand factor (recombinant)]</td>
</tr>
<tr>
<td>Bispecific factor IXa- and factor X-directed antibody</td>
<td>Hemlibra® (emicizumab-kowh)</td>
</tr>
</tbody>
</table>

The following information provides the indications and criteria for which specific clotting factors and coagulant blood products are considered proven:

**Congenital Factor XIII Deficiency (i.e., Fibrin Stabilizing Factor Deficiency)**

**Factor XIII (plasma-derived) [Corifact] is proven and medically necessary when both of the following criteria are met:**
- Diagnosis of congenital factor XIII deficiency; **and**

- **One** of the following:
  - Routine prophylactic treatment; **or**
  - Peri-operative management of surgical bleeding; **or**
  - Treatment of bleeding episodes.

**Coagulation Factor XIII A-subunit (recombinant) [Tretten] is proven and medically necessary when both of the following criteria are met:**
- Diagnosis of congenital factor XIII A-subunit deficiency; **and**

- **One** of the following:
  - Routine prophylactic treatment; **or**
  - Peri-operative management of surgical bleeding; **or**
  - Treatment of bleeding episodes.
Von Willebrand Disease (VWD)

Factor VIII (plasma-derived)/von Willebrand Factor Complex (plasma-derived) [Humate-P] is proven and medically necessary when both of the following criteria are met:

- **One** of the following:
  - Diagnosis of severe von Willebrand disease; or
  - **Both** of the following:
    - Diagnosis of mild or moderate von Willebrand disease; and
    - History of failure, contraindication or intolerance to treatment with desmopressin.

- **One** of the following:
  - Treatment of bleeding episodes; or
  - Peri-operative management of surgical bleeding.

Factor VIII (plasma-derived)/von Willebrand Factor Complex (plasma-derived) [Alphanate] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of mild or moderate von Willebrand disease; and
- Peri-operative management of surgical bleeding; and
- History of failure, contraindication or intolerance to treatment with desmopressin.

Factor VIII (plasma-derived)/von Willebrand Factor Complex (plasma-derived) [Wilate] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of von Willebrand disease; and
  - **One** of the following:
    - Routine prophylactic treatment; or
    - Peri-operative management of surgical bleeding; or
    - Treatment of bleeding episodes.

Von Willebrand factor (recombinant) [Vonvendi] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of von Willebrand disease; and
  - **One** of the following:
    - Routine prophylactic treatment; or
    - Peri-operative management of surgical bleeding; or
    - Treatment of bleeding episodes.

Congenital Factor VII Deficiency

Factor VIIa (recombinant) [NovoSeven RT] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of congenital factor VII deficiency; and
  - **One** of the following:
    - Routine prophylactic treatment; or
    - Treatment of bleeding episodes.

Hemophilia A (i.e., Factor VIII Deficiency, Classical Hemophilia)

Factor VIII (plasma-derived)/von Willebrand Factor Complex (plasma-derived) [Alphanate or Humate-P], Factor VIII (plasma-derived) [Hemofil M or Koâte-DVI], and Factor VIII (recombinant) [Advate, Kogenate FS, Kovaltry, NovoEight, Nuwiq, or Recombinate] are proven and medically necessary when both of the following criteria are met:

- Diagnosis of hemophilia A; and
  - **One** of the following:
    - Routine prophylactic treatment; or
    - Peri-operative management of surgical bleeding; or
    - Treatment of bleeding episodes.
Factor VIII (plasma-derived)/von Willebrand Factor Complex (plasma-derived) [Wilate] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Treatment of bleeding episodes.

Additional information to support medical necessity review where applicable:

Antihemophilic Factor (Recombinant) [Helixate], and Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] are not medically necessary for treatment of hemophilia A for the following:

- Routine prophylactic treatment;
- Perioperative management of surgical bleeding;
- Treatment of bleeding episodes.

Published clinical evidence does not demonstrate superiority in efficacy and treatment adherence of Helixate, or Esperoct to other available recombinant factor products.

Antihemophilic Factor (recombinant) [Xyntha] is proven for the treatment of hemophilia A.

Additional information to support medical necessity review where applicable:

Antihemophilic Factor (recombinant) [Xyntha] is medically necessary when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.
  
  and

- One of the following:
  - Submission of documentation showing failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve appropriate trough level) after a trial of three of the following recombinant factor products:
    - Advate
    - Kogenate FS
    - Kovaltry
    - NovoEight
    - Nuwiq
    - Recombinate
  
  or

  - Submission of documentation showing history of hypersensitivity to three of the following recombinant factor products:
    - Advate
    - Kogenate FS
    - Kovaltry
    - NovoEight
    - Nuwiq
    - Recombinate
  
  or

  - Physician attestation that patient would preferentially benefit from Xyntha based on one of the following:
    - Patient is at high risk for the development of inhibitors (e.g., family history of inhibitors and success with product, current treatment less than 50 days, high risk genetic mutation, history of initial intensive therapy greater than 5 days)
    - Patient has developed inhibitors
    - Patient has undergone immune tolerance induction/immune tolerance therapy
  
  or

  - All of the following:
o Patient is currently on Xyntha; and

  o One of the following:
    ▪ Submission of documentation showing failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve appropriate trough level) after a trial of three of the following recombinant factor products:
      - Advate
      - Kogenate FS
      - Kovaltry
      - NovoEight
      - Nuwiq
      - Recombinate
    or
    ▪ Submission of documentation showing history of hypersensitivity to three of the following recombinant factor products:
      - Advate
      - Kogenate FS
      - Kovaltry
      - NovoEight
      - Nuwiq
      - Recombinate
    or
    ▪ Physician attestation that patient would preferentially benefit from Xyntha based on one of the following:
      - Patient is at high risk for the development of inhibitors (e.g., family history of inhibitors and success with product, current treatment less than 50 days, high risk genetic mutation, history of initial intensive therapy greater than 5 days)
      - Patient has developed inhibitors
      - Patient has undergone immune tolerance induction/immune tolerance therapy

**Antihemophilic Factor (recombinant), FC Fusion Protein [Eloctate] is proven when all of the following criteria are met:**

  1. Diagnosis of hemophilia A; and
  2. One of the following:
     1. Routine prophylactic treatment; or
     2. Peri-operative management of surgical bleeding; or
     3. Treatment of bleeding episodes.

**Additional information to support medical necessity review where applicable:**

**Antihemophilic Factor (recombinant), FC Fusion Protein [Eloctate] is medically necessary for the treatment of Hemophilia A when all of the following criteria are met:**

  1. Diagnosis of hemophilia A; and
  2. Patient is not a suitable candidate for treatment with shorter half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, NovoEight, Nuwiq, or Recombinate] as attested by the prescribing physician; and
  3. One of the following:
     1. Both of the following:
        1. Dose does not exceed 50 i.u./kg; and
        2. Infusing no more frequently than every 4 days.
         or
     2. Requested dosage regimen does not exceed 12.5 i.u./kg/day; or
     3. Both of the following:
        1. Patient is less than 6 years of age; and
        2. One of the following:
           1. PK testing results suggest that dosing more intensive than 50 i.u./kg is required; or
           2. PK testing results suggest that dosing more frequently than every 3 to5 days is required; or
           3. PK testing results suggest that dosing more intensive that 14.5 i.u./kg/day is required.
Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl [Altuviiio] is proven when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.

Additional information to support medical necessity review where applicable:

Antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl [Altuviiio] is medically necessary for the treatment of Hemophilia A when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes and
  - Patient is not a suitable candidate for treatment with shorter half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwq, or Recombinate] as attested by the prescribing physician; and
- Both of the following:
  - Dose does not exceed 50 IU/kg; and
  - Patient is infusing no more frequently than every 7 days

Antihemophilic Factor (recombinant), Pegylated-auct [Jivi] is proven when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes
  and
  - Patient has previously received Factor VIII replacement therapy; and
  - Patient is 12 years of age or older

Additional information to support medical necessity review where applicable:

Antihemophilic Factor (recombinant), Pegylated-auct [Jivi] is medically necessary for the treatment of Hemophilia A when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes
  and
  - Patient has previously received Factor VIII replacement therapy; and
  - Patient is 12 years of age or older;
  and
  - Patient is not a candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [e.g., Advate, Kogenate FS, Kovaltry, Novoeight, Nuwq, or Recombinate] as attested by the prescribing physician; and
  - Patient is not to receive routine infusions more than 2 times per week

Antihemophilic Factor (recombinant), Single Chain [Afstyla] is proven when both of the following criteria are met:

- Diagnosis of hemophilia A; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.
Additional information to support medical necessity review where applicable:

**Antihemophilic Factor (recombinant), Single Chain [Afstyla]** is medically necessary for the treatment of Hemophilia A when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician; and
- **One** of the following:
  - Patient is not to receive routine infusions more frequently than 3 times per week; or
  - **Both** of the following:
    - Patient is less than 12 years of age; and
    - Pharmacokinetic (PK) testing results suggest that more frequently than 3 times per week dosing is required.

**Antihemophilic Factor (recombinant), Pegylated [Adynovate]** is proven when both of the following criteria are met:

- Diagnosis of hemophilia A; and
- **One** of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.

Additional information to support medical necessity review where applicable:

**Antihemophilic Factor (recombinant), Pegylated [Adynovate]** is medically necessary for the treatment of Hemophilia A when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII (recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or Recombinate] as attested by the prescribing physician; and
- **One** of the following:
  - Both of the following:
    - Patient is not to receive routine infusions more frequently than 2 times per week; and
    - Patient is not to receive a routine dose greater than 50 IU/kg.
  - All of the following:
    - Patient is less than 12 years of age; and
    - Patient is not to receive routine infusions more frequently than 2 times per week; and
    - Patient is not to receive a routine dose greater than 70 IU/kg.

**Emicizumab-kxwh [Hemlibra]** is proven for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A when all of the following criteria are met (please note that emicizumab-kxwh [Hemlibra] is a self-injectable medication that should be obtained under the member’s pharmacy benefit unless the following criteria are met):

- **For initial therapy**:
  - Diagnosis of hemophilia A; and
  - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis); and
  - **One** of the following:
    - Patient is less than 7 years of age; or
    - Patient is 7 years of age or older and cannot self-inject and does not have a caretaker who can be trained to administer Hemlibra; or
    - Patient is receiving Hemlibra from a contracted hemophilia treatment center.

- **For continuation of therapy**:
  - Diagnosis of hemophilia A; and
  - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis); and
  - Documentation of positive clinical response to Hemlibra therapy; and
  - **One** of the following:
    - Patient is less than 7 years of age; or
- Patient is 7 years of age or older and cannot self-inject and does not have a caretaker who can be trained to administer Hemlibra; or
- Patient is receiving Hemlibra from a contracted hemophilia treatment center.

Additional information to support medical necessity review where applicable:

Emicizumab-kxwh [Hemlibra] is medically necessary when all of the following criteria are met (note that emicizumab-kxwh [Hemlibra] is a self-injectable medication that should be obtained under the member’s pharmacy benefit unless the following criteria are met):

- **For initial therapy:**
  - One of the following:
    - All of the following:
      - Diagnosis of severe hemophilia A; and
      - Documentation of endogenous factor VIII level less than 1% of normal factor VIII ($< 0.01$ i.u./mL); and
      - Physician attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes.
    - or
    - All of the following:
      - One of the following:
        - Both of the following:
          - Diagnosis of moderate hemophilia A; and
          - Documentation of endogenous factor VIII level $\geq 1\% < 5\%$ (greater than or equal to 0.01 i.u./mL to less than 0.05 i.u./mL);
        - or
        - Both of the following:
          - Diagnosis of mild hemophilia A; and
          - Documentation of endogenous factor VIII level $\geq 5\%$ (greater than 0.05 i.u./mL).
    - Submission of medical records (e.g., chart notes, laboratory values) documenting a failure to meet clinical goals (e.g., continuation of spontaneous bleeds, inability to achieve appropriate trough level, previous history of inhibitors) after a trial of prophylactic factor VIII replacement products; and
    - Physician attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes; or
  - Both of the following:
    - Diagnosis of hemophilia A; and
    - Patient has developed high-titer factor VIII inhibitors ($\geq 5$ Bethesda units [BU]);
    - and
    - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis); and
    - One of the following:
      - Patient is less than 7 years of age; or
      - Patient is 7 years of age or older and cannot self-inject and does not have a caretaker who can be trained to administer Hemlibra; or
      - Patient is receiving Hemlibra from a contracted hemophilia treatment center.

- **For continuation of therapy:**
  - Patient has previously been treated with Hemlibra; and
  - Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis); and
  - Documentation of positive clinical response; and
  - Physician attestation that the patient is not to receive extended half-life factor VIII replacement products (e.g., Eloctate, Adynovate, Afstyla, Jivi) for the treatment of breakthrough bleeding episodes; and
  - One of the following:
    - Patient is less than 7 years of age; or
    - Patient is 7 years of age or older and cannot self-inject and does not have a caretaker who can be trained to administer Hemlibra; or
    - Patient is receiving Hemlibra from a contracted hemophilia treatment center.
Anti-Inhibitor Coagulant Complex (plasma-derived) [FEIBA] is proven and medically necessary when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- Documentation of inhibitors (e.g., Bethesda inhibitor assay); and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.

Factor VIIa (recombinant) [NovoSeven RT] is proven and medically necessary when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- Documentation of inhibitors (e.g., Bethesda inhibitor assay); and
- One of the following:
  - Treatment of bleeding episodes; or
  - Peri-operative management of surgical bleeding.

Factor VIIa (recombinant)-jncw [Sevenfact] is proven and medically necessary when all of the following criteria are met:

- Diagnosis of hemophilia A; and
- Treatment and control of bleeding episodes.

Factor VIIa (recombinant) [NovoSeven RT] and antihemophilic factor (recombinant), porcine sequence [Obizur] are proven and medically necessary when both of the following criteria are met:

- Diagnosis of acquired factor VIII hemophilia (e.g., acquired hemophilia A, Factor VIII deficiency); and
- Treatment or prevention of bleeding episodes.

**Hemophilia B (i.e., Congenital Factor IX Deficiency, Christmas Disease)**

Factor IX (plasma-derived) [AlphaNine SD, Mononine, or Profilnine SD] is proven and medically necessary when both of the following criteria are met:

- Diagnosis of hemophilia B; and
- One of the following:
  - Routine prophylactic treatment; or
  - Treatment of bleeding episodes.

Factor IX (recombinant) [BeneFIX or Rixubis], Coagulation Factor IX (recombinant), Fc Fusion Protein (Alprolix) and Coagulation Factor IX (recombinant), albumin fusion protein (Idelvion) are proven and medically necessary when both of the following criteria are met:

- Diagnosis of hemophilia B; and
- One of the following:
  - Routine prophylactic treatment; or
  - Peri-operative management of surgical bleeding; or
  - Treatment of bleeding episodes.

Additional information to support medical necessity review where applicable:

Coagulation Factor IX (recombinant) [Ixinity] and Coagulation Factor IX (recombinant), GlycoPEGylated [Rebinyn] are not medically necessary for treatment of hemophilia B for the following:

- Routine prophylactic treatment; or
- Peri-operative management of surgical bleeding; or
- Treatment of bleeding episodes.

Published clinical evidence does not demonstrate superiority in efficacy and treatment adherence of Ixinity or Rebinyn to other available recombinant factor products.
Diagnosis of hemophilia B; and
Documentation of inhibitors (e.g., Bethesda inhibitor assay); and
One of the following:
  o Routine prophylactic treatment; or
  o Peri-operative management of surgical bleeding; or
  o Treatment of bleeding episodes.

Factor VIIa (recombinant) [NovoSeven RT] is proven and medically necessary when all of the following criteria are met:
Diagnostic of hemophilia B; and
Documentation of inhibitors (e.g., Bethesda inhibitor assay); and
One of the following:
  o Treatment of bleeding episodes; or
  o Peri-operative management of surgical bleeding.

**Fibrinogen Deficiency (i.e., Factor I Deficiency)**
Fibrinogen Concentrate (plasma-derived) [Fibryga, RiaSTAP] is proven and medically necessary when all of the following criteria are met:
Diagnostic of congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia; and
Treatment of bleeding episodes.

**Glanzmann Thrombasthenia**
Factor VIIa (recombinant) [NovoSeven RT] is proven and medically necessary when all of the following criteria are met:
Diagnostic of Glanzmann’s thrombasthenia; and
Refractory to platelet transfusions; and
One of the following:
  o Treatment of bleeding episodes; or
  o Peri-operative management of surgical bleeding.

**Congenital Factor X Deficiency**
Coagulation Factor X (human) [Coagadex] is proven and medically necessary when both of the following criteria are met:
Diagnostic of congenital Factor X deficiency; and
One of the following:
  o Routine prophylactic treatment; or
  o Treatment of bleeding episodes; or
  o Peri-operative management of surgical bleeding.

**Applicable Codes**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J7170</td>
<td>Injection, emicizumab-kxwh, 0.5 mg</td>
</tr>
<tr>
<td>J7175</td>
<td>Injection, factor X (human), 1 i.u.</td>
</tr>
<tr>
<td>J7177</td>
<td>Injection, human fibrinogen concentrate (Fibryga), 1 mg</td>
</tr>
<tr>
<td>J7178</td>
<td>Injection, human fibrinogen concentrate, not otherwise specified, 1 mg</td>
</tr>
<tr>
<td>J7179</td>
<td>Injection, von Willebrand factor (recombinant), (Vonvendi), 1 i.u. vWF: RCo</td>
</tr>
<tr>
<td>J7180</td>
<td>Injection, factor XIII (antihemophilic factor, human), 1 i.u.</td>
</tr>
<tr>
<td>HCPCS Code</td>
<td>Description</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>J7181</td>
<td>Injection, factor XIII A-subunit, (recombinant), per i.u. (Tretten)</td>
</tr>
<tr>
<td>J7182</td>
<td>Injection, factor VIII, (antihemophilic factor, recombinant), (Novoeight), per i.u.</td>
</tr>
<tr>
<td>J7183</td>
<td>Injection, von Willebrand factor complex (human), Wilate, 1 i.u. vWF: RCo</td>
</tr>
<tr>
<td>J7185</td>
<td>Injection, factor VIII (antihemophilic factor, recombinant) (XYNTHA), per i.u.</td>
</tr>
<tr>
<td>J7186</td>
<td>Injection, antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII i.u.</td>
</tr>
<tr>
<td>J7187</td>
<td>Injection, von Willebrand factor complex (Humate-P), per i.u. VWF: RCO</td>
</tr>
<tr>
<td>J7188</td>
<td>Injection, Factor VIII (antihemophilic factor, recombinant) (Obizur), per i.u.</td>
</tr>
<tr>
<td>J7189</td>
<td>Factor VIIIa (antihemophilic factor, recombinant), (NovoSeven RT), 1 mcg</td>
</tr>
<tr>
<td>J7190</td>
<td>Factor VIII (antihemophilic factor, human) per i.u.</td>
</tr>
<tr>
<td>J7192</td>
<td>Factor VIII (antihemophilic factor, recombinant) per i.u., not otherwise specified</td>
</tr>
<tr>
<td>J7193</td>
<td>Factor IX (antihemophilic factor, purified, nonrecombinant) per i.u.</td>
</tr>
<tr>
<td>J7194</td>
<td>Factor IX complex, per i.u.</td>
</tr>
<tr>
<td>J7195</td>
<td>Injection, factor IX (antihemophilic factor, recombinant) per i.u., not otherwise specified</td>
</tr>
<tr>
<td>J7198</td>
<td>Anti-inhibitor, per i.u.</td>
</tr>
<tr>
<td>J7199</td>
<td>Hemophilia clotting factor, not otherwise classified</td>
</tr>
<tr>
<td>J7200</td>
<td>Injection, factor IX, (antihemophilic factor, recombinant), Rixubis, per i.u.</td>
</tr>
<tr>
<td>J7201</td>
<td>Injection, factor IX, Fc fusion protein, (recombinant), Alprolix, 1 i.u.</td>
</tr>
<tr>
<td>J7202</td>
<td>Injection, factor IX, albumin fusion protein (recombinant), (Idelvion), 1 i.u.</td>
</tr>
<tr>
<td>J7203</td>
<td>Injection factor IX, (antihemophilic factor, recombinant), glycopegylated, (Rebiny), 1 i.u.</td>
</tr>
<tr>
<td>J7204</td>
<td>Injection, factor VIII, anthemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu</td>
</tr>
<tr>
<td>J7205</td>
<td>Injection, factor VIII Fc fusion protein (recombinant), per i.u.</td>
</tr>
<tr>
<td>J7206</td>
<td>Injection, factor VIII, (antihemophilic factor, recombinant), pegylated, 1 i.u.</td>
</tr>
<tr>
<td>J7207</td>
<td>Injection, factor VIII, (antihemophilic factor, recombinant), pegylated-aucI, (Jivi), 1 i.u.</td>
</tr>
<tr>
<td>J7209</td>
<td>Injection, factor VIII (antihemophilic factor, recombinant), (Nuwiq), 1 i.u.</td>
</tr>
<tr>
<td>J7210</td>
<td>Injection, factor VIII, (antihemophilic factor, recombinant), (Alstyla), 1 i.u.</td>
</tr>
<tr>
<td>J7211</td>
<td>Injection, factor VIII, (antihemophilic factor, recombinant), (Kovaltry), 1 i.u.</td>
</tr>
<tr>
<td>J7212</td>
<td>Factor VIIIa (antihemophilic factor, recombinant)-jncw (Sevenfact), 1 mcg</td>
</tr>
<tr>
<td>J7213</td>
<td>Injection, coagulation factor IX (recombinant), lxinity, 1 IU</td>
</tr>
<tr>
<td>J7214</td>
<td>Injection, Factor VIII/von Willebrand factor complex, recombinant (Altuviiio), per Factor VIII IU</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D66</td>
<td>Hereditary factor VIII deficiency</td>
</tr>
<tr>
<td>D67</td>
<td>Hereditary factor IX deficiency</td>
</tr>
<tr>
<td>D68.00</td>
<td>Von Willebrand’s disease, unspecified</td>
</tr>
<tr>
<td>D68.01</td>
<td>Von Willebrand disease, type 1</td>
</tr>
<tr>
<td>D68.020</td>
<td>Von Willebrand disease, type 2A</td>
</tr>
<tr>
<td>D68.021</td>
<td>Von Willebrand disease, type 2B</td>
</tr>
<tr>
<td>D68.022</td>
<td>Von Willebrand disease, type 2M</td>
</tr>
<tr>
<td>D68.023</td>
<td>Von Willebrand disease, type 2N</td>
</tr>
<tr>
<td>D68.029</td>
<td>Von Willebrand disease, type 2, unspecified</td>
</tr>
<tr>
<td>D68.03</td>
<td>Von Willebrand disease, type 3</td>
</tr>
<tr>
<td>D68.04</td>
<td>Acquired von Willebrand disease</td>
</tr>
</tbody>
</table>
### Diagnosis Code | Description
--- | ---
D68.09 | Other von Willebrand disease
D68.2 | Hereditary deficiency of other clotting factors
D68.31 | Acquired hemophilia
D69.1 | Qualitative platelet defects

### Background

Factor VIIa (FVIIa) is a vitamin K-dependent glycoprotein made up of 406 amino acid residues, and is structurally similar to human plasma-derived factor VIIa. FVIIa promotes hemostasis by forming complexes with tissue factor and activating coagulation factors in the intrinsic pathway: factor X to factor Xa, and factor IX to factor IXa. Activated factor Xa, complexed with other factors, converts prothrombin to thrombin and fibrinogen to fibrin to form a hemostatic plug.5,27

Factor XIII (FXIII) is a naturally occurring glycoprotein in plasma that promotes cross-linking of fibrin during the coagulation process, and protects the newly formed clot from fibrinolysis. FXIII is a proenzyme which is activated in the presence of calcium ion, to form activated factor XIIIa. The activated form is homodimeric, with only the A-subunit having intracellular activity. The B-subunit has no enzymatic activity and functions to stabilize the structure against proteolysis.1,27

Coagulation factor XIII A-subunit is a recombinant human factor XIII-A(2) homodimer composed of 2 factor XIII A-subunits. Recombinant coagulation factor XIII A-subunit binds to free human factor XIII B-subunit and is activated by thrombin in the presence of calcium. Once activated, it increases the mechanical strength of fibrin clots, retards fibrinolysis, and enhances platelet adhesion to the site of injury in a dose-dependent manner.27,33

Antihemophilic Factor VIII (FVIII) Human is a dried concentrate of Factor VIII derived from pooled human plasma. FVIII is the coagulant portion of the Factor VIII complex in plasma. FVIII acts as a co-factor for Factor IX to activate Factor X, ultimately causing the formation of thrombin and fibrin, promoting platelet aggregation and adhesion to damaged vascular endothelium.7,27

Antihemophilic Factor VIII / von Willebrand Factor Complex (human) is a lyophilized concentrate of factor VIII and von Willebrand Factor, which facilitates the activation of factor X ultimately causing the formation of thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium.2-4,27

Antihemophilic Factor (recombinant), FC Fusion Protein is a fusion protein that temporarily replaces the missing Coagulation Factor VIII needed for effective hemostasis. It contains the Fc 12 region of human immunoglobulin G1 (IgG1), which binds to the neonatal Fc receptor (FcRn). FcRn is part of a naturally occurring pathway that delays lysosomal degradation of immunoglobulins by cycling them back into circulation and prolonging their plasma half-life.36

Antihemophilic Factor (recombinant), Porcine Sequence temporarily replaces the inhibited endogenous factor VIII that is needed for effective hemostasis in patients with acquired hemophilia A.38

Recombinant antihemophilic Factor VIII is not derived from human blood. It is a lyophilized preparation of factor VIII, which facilitates the activation of factor X ultimately causing the formation of thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium.8-12, 27, 31-32, 40-42

All forms of factor IX (FIX) achieve hemostasis through the same mechanism. A complex of factor VII and tissue factor (via the extrinsic coagulation pathway) and factor XIa (via the intrinsic pathway) activate factor IX which, in combination with factor VIII:C, activates factor X to Xa. Through this pathway, prothrombin is converted to thrombin which, in turn, converts fibrinogen to fibrin clot.14-18, 27, 30, 39, 54

The exact mechanism of action of anti-inhibitor complex (AICC) is unknown. It may be related to one or more of the active clotting factors and their ability to bypass the factor VIII inhibitor. In vitro experiments suggest the possibility of a factor Xa-like substance; or a complex of FVIII:C:Ag, factor IXa, and phospholipid as the active principle, which is only minimally inhibited by an inhibitor.13,27
Factor IX Fc fusion protein recombinant transiently replaces missing coagulation factor IX required to achieve hemostasis during bleeding episodes in patients with factor IX deficiency. The Fc region of the drug binds to the neonatal Fc receptor (FcRn). FcRn assists in the delay of lysosomal degradation of immunoglobulins by cycling them back into circulation and increasing their plasma half-life. Hemophilia B patients have a prolonged activated partial thromboplastin time (aPTT), which is an established test for the biological activity of factor IX; factor IX Fc fusion protein recombinant therapy shortens the aPTT over the effective dosing period.27,34

Fibrinogen (coagulation factor I) is a soluble plasma glycoprotein and a physiological substrate of 3 enzymes: thrombin, factor Xlla, and plasmin. Thrombin converts fibrinogen into fibrin. Fibrin is stabilized in the presence of calcium ions and by activated Factor XIII. Factor Xlla induces cross-linking of fibrin polymers which result in the fibrin clot being more elastic and more resistant to fibrinolysis. The cross-linked fibrin is the end result of the coagulation cascade. Cross-linked fibrin is the end result of the coagulation cascade, and provides tensile strength to a primary hemostatic platelet plug and structure to the vessel wall.20, 27, 29

Antihemophilic factor VIII (recombinant) pegylated is a temporarily replaces coagulation factor VIII, thereby providing hemostasis in patients with congenital hemophilia A. Pegylation of the parent molecule (antihemophilic factor VIII recombinant) extends the half-life via reduced binding to the factor VIII clearance receptor (LRP1).27, 44, 52, 55

Coagulation Factor IX (recombinant), albumin fusion protein, temporarily replaces absent coagulation Factor IX to provide adequate hemostasis. The recombinant albumin is fused with recombinant Factor IX to extend the half-life of Factor IX.27, 43

Coagulation Factor X (human) is converted from its inactive form to the active form (Factor Xa) and with Factor Va on the phospholipid surface forms a prothrombinase complex which activates prothrombin to thrombin in the presence of calcium ions. Thrombin acts upon soluble fibrinogen and Factor XIII to generate a cross-linked fibrin clot.27, 45

Von Willebrand factor (recombinant) reduces factor VIII clearance by acting as a carrier protein and protecting factor VIII from rapid proteolysis. It promotes hemostasis by mediating platelet adhesion to damaged vascular subendothelial matrix (e.g., collagen) and platelet aggregation.27, 46

Hemlibra (emicizumab-kxwh) is a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific antibody structure binding factor IXa and factor X. It bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.51

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] temporarily replaces the missing coagulation factor VIII needed for effective hemostasis. Altuviiio has demonstrated 3- to 4-fold prolonged half-life relative to other standard and extended half-life FVIII products.60

**Benefit Considerations**

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. Refer to the Policy and Procedure addressing the treatment of serious rare diseases.

**Clinical Evidence**

**Proven**

**Congenital Factor XIII Deficiency**

In a multinational, open-label, single-arm, phase 3 trial, researchers evaluated the efficacy and safety of prophylactic treatment with recombinant FXIII (rFXIII) [Tretten] in congenital FXIII-A subunit deficiency.23, 33 Forty-one patients ≥ 6 years of age (mean,
26.4; range, 7-60) with confirmed congenital FXIII-A subunit deficiency were enrolled into the trial which consisted of a 4-week run-in period, followed by a 52-week treatment period (visits 2-15) of monthly (28 ±2 days) IV doses of 35 i.u./kg of rFXIII. During the rFXIII treatment period, 5 bleeding episodes (all trauma induced) in 4 patients were treated with FXIII-containing products. Crude mean bleeding rate was significantly lower than the historic bleeding rate (0.138 vs 2.91 bleeds/patient/year, respectively) for on-demand treatment. Transient, non-neutralizing, low-titer anti-rFXIII antibodies (Abs) developed in 4 patients; however, this did not result in allergic reactions, changes in any bleeds requiring treatment, or changes in FXIII pharmacokinetics during the trial or follow-up. These non-neutralizing Abs declined below detection limits in all 4 patients despite further exposure to rFXIII or other FXIII-containing products. Researchers conclude that prophylactic treatment with rFXIII is safe and effective in preventing bleeding episodes in patients with congenital FXIII-A subunit deficiency.

Factor XIII concentrate (human) [Corifact] labeling included expanded information in regards to use of rFXIII for peri-operative treatment of bleeds.1 Out of the 41 patients included in the trial, 5 patients underwent surgical procedures (4 were elective and 1 was an emergency). Of the 4 elective surgeries, 3 patients received rFXIII prior to surgery (0 to 7 days prior to surgery) with no post-operative bleeding. One patient who received rFXIII 7 days prior to surgery experienced bleeding post-extraction of all four wisdom teeth. The bleeding was stopped four hours after the oral surgery with an additional dose of rFXIII (50% of the patient’s routine dose). One patient who required emergency surgery was pre-treated with plasma.

**Von Willebrand Disease (VWD)**

Gill et al. conducted a prospective, open-label, multinational study which evaluated the safety, efficacy, and optimal dosing of a VWF/FVIII concentrate [Humate-P] in patients with von Willebrand disease (VWD) undergoing elective surgery and expected to require at least two consecutive days of perioperative treatment with a VWF/FVIII concentrate.26 Dosing of factor was based on VWF ristocetin cofactor (VWF:RCo) and FVIII pharmacokinetic assessments performed before surgery. The studied population was composed of 33 adults and 9 children who completed the PK infusion phase. Effective hemostasis was achieved in 91.4% (32/35) of subjects immediately after surgery. Reported median terminal VWF:RCo half-life was 11.7 h, and median incremental in vivo recovery was 2.4 i.u. dL(-1) per i.u. kg(-1) infused. Three patients developed major hemorrhage after the immediate postoperative period. Median VWF/FVIII concentrate loading doses ranged from 42.6 i.u. VWF:RCo kg(-1) (oral surgery) to 61.2 i.u. VWF:RCo kg(-1) (major surgery), with a median of 10 (range, 2-55) doses administered per patient. Eleven patients experienced a total of 25 postoperative bleeding events, most of which were categorized as mild (16) or moderate (8). Researchers conclude that the results of this trial indicate that this VWF/FVIII concentrate is safe and effective in the prevention of excessive bleeding during and after surgery in individuals with VWD.

Researchers conducted a prospective, open-label, multicenter, non-randomized study which evaluated the safety and efficacy of a factor VIII (FVIII)/VWF concentrate [Humate-P] when used in treatment regimens based on VWF:ristocetin cofactor (VWF:RCo) activity in subjects with VWD in which desmopressin was known or suspected to be inadequate in situations requiring urgent and necessary surgery.24 Thirty-nine eligible patients with 42 evaluable surgical treatment events were included. Researchers reported the median loading dose based upon VWF:RCo activity was 82.3 international units/kilogram (i.u. kg(-1); median 32.5-216.8 i.u. kg(-1)), and the median maintenance dose per infusion was 52.8 i.u. kg(-1) (range 24.2-196.5 i.u. kg(-1)) for a median of 3 days (range 1-50 days). The median number of infusions per event was 6 (range 1-67 infusions). A total of 55 adverse events (AEs) were reported in 24 (57.1%) of 42 surgical treatment events and 3 of those AE events (which included peripheral edema, extremity pain and pseudo-thrombocytopenia) were reported as potentially treatment-related. No serious drug-related AEs or thrombotic events were reported. Researchers concluded that this study supports the safety and efficacy of treatment with FVIII/VWF concentrate for the prevention of surgical hemorrhage in patients with VWD when administered in doses calculated in VWF:RCo units.

Forty-five patients with von Willebrand disease (VWD) who received on demand von Willebrand factor/coagulation factor VIII complex (human) [Wilate] were evaluated in prospective clinical trials.4 bleeding was successfully controlled in 84.1% (95% confidence interval [CI], 81.8% to 86.2%) of episodes (898 of 1068 episodes); additionally, bleeding was successfully controlled in 93% of episodes in the 25 patients with VWD type 3. Non-successful treatment of a bleeding episode was documented if any of the following criteria was met: 1) the episodes was also treated with another VWF-containing product (excluding whole blood); 2) the patient required a blood transfusion during the bleeding episode; 3) the daily dosage of FVIII/VWF complex was 50% or greater above the initial required dose during follow-up treatment (for bleeding episodes requiring more than one day of treatment); 4) except for cases of gastrointestinal bleeding, FVIII/VWF complex was required for more than 4 days for the treatment of severe bleeding, more than 3 days for the treatment of moderate bleeding, or more than 2 days for the treatment of minor bleeding; and 5) the final bleeding episode had a moderate or none efficacy rating. Overall, most bleeding episodes were
treated with FVIII/VWF complex for 1 to 3 days; however, patients with gastrointestinal bleeding the duration could be up to 7 days.

**Congenital Factor VII Deficiency, Acquired Factor VIII Deficiency, Hemophilia A with Inhibitors, and Hemophilia B with Inhibitors**

Mariani et al conducted a multi-center, prospective, observational, web-based study protocol to collect and describe treatment modalities and outcomes in congenital FVII deficiency (STER [Seven Treatment Evaluation Registry]). Forty-one surgical operations (24 ‘major’ and 17 ‘minor’) were performed in 34 patients diagnosed with FVII deficiency and administered recombinant activated Factor VII (rFVIIa) [NovoSeven]. Bleeding occurred during three major interventions of orthopedic surgery; however, rFVIIa was administered at very low dose in each case. An antibody to FVII was observed in one patient who underwent multiple dental extractions. No thromboses were reported during the 30-d follow up period. Replacement therapy with rFVIIa for surgery in FVII deficient patients is effective and safe when minimally effective doses were used, which, during the period of maximum bleeding risk (the day of operation), was calculated (Receiver Operated Characteristic analysis) to be of at least 12 μg/kg/body weight per single dose and no less than three administrations.

**Hemophilia A**

Mahlangu et al evaluated the use of emicizumab in persons who have hemophilia A without factor VIII inhibitors as prophylactic therapy in a phase 3, multicenter trial. The authors randomly assigned patients aged 12 years or older who had been receiving episodic treatment with factor VIII to receive a subcutaneous maintenance dose of emicizumab of 1.5 mg per kilogram of body weight per week (group A) or 3.0 mg per kilogram every 2 weeks (group B) or no prophylaxis (group C). The primary end point was the difference in rates of treated bleeding between patient groups. Participants who had been receiving factor VIII prophylaxis received emicizumab at a maintenance dose of 1.5 mg per kilogram per week (group D). For patients who participated in the noninterventional study, intraindividual studies were performed. One hundred fifty two patients enrolled in the study. The annualized bleeding rate was 1.5 events (95% confidence interval [CI], 0.9 to 2.5) in group A and 1.3 events (95% CI, 0.8 to 2.3) in group B, as compared with 38.2 events (95% CI, 22.9 to 63.8) in group C; thus, the rate was 96% lower in group A and 97% lower in group B (p < 0.001 for both comparisons). A total of 56% of the participants in group A and 60% of those in group B had no treated bleeding events, as compared with those in group C, who all had treated bleeding events. In the intraindividual comparison involving 48 participants, emicizumab prophylaxis resulted in an annualized bleeding rate that was 68% lower than the rate with previous factor VIII prophylaxis (p < 0.001). The most frequent adverse event was low-grade injection-site reaction. There were no thrombotic or thrombotic microangiopathy events, development of antidrug antibodies, or new development of factor VIII inhibitors. The authors conclude that prophylaxis with emicizumab led to a significantly lower bleeding rate than no prophylaxis among persons with hemophilia A without inhibitors; more than half the participants who received prophylaxis had no treated bleeding events. In an intraindividual comparison, emicizumab therapy led to a significantly lower bleeding rate than previous factor VIII prophylaxis.

The safety, efficacy, and pharmacokinetics of Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] were evaluated in two multicenter, prospective, open-label clinical studies (one study in adults and adolescents ≥ 12 years of age and one pediatric study in children < 12 years of age in previously treated patients (PTPs) with severe hemophilia A (< 1% endogenous Factor VIII activity or a documented genetic mutation consistent with severe hemophilia A). All studies evaluated the efficacy of routine prophylaxis with a weekly dose of 50 IU/kg and determined hemostatic efficacy in the treatment of bleeding episodes and during perioperative management in subjects undergoing major or minor surgical procedures. The completed adult and adolescent study enrolled a total of 159 PTPs (158 male and 1 female subjects) with severe hemophilia A. Subjects were aged 12 to 72 years and included 25 adolescent subjects aged 12 to 17 years. All 159 enrolled subjects received at least one dose of Altuviiio and were evaluable for efficacy. A total of 149 subjects (93.7%) completed the study. The ongoing pediatric study enrolled 67 male PTPs. The efficacy of weekly 50 IU/kg Altuviiio as routine prophylaxis was evaluated as estimated by the mean annualized bleed rate (ABR) and by comparing the ABR during on-study prophylaxis vs. the ABR during pre-study FVIII prophylaxis. A total of 133 adults and adolescents, who were on pre-study FVIII prophylaxis, were assigned to receive Altuviiio for routine prophylaxis at a dose of 50 IU/kg IV once weekly for 52 weeks (Arm A). An additional 26 subjects, who were on pre-study episodic (on-demand) treatment with FVIII, received episodic (on-demand) treatment with Altuviiio at doses of 50 IU/kg IV for 26 weeks, followed by routine prophylaxis at a dose of 50 IU/kg IV once weekly for 26 weeks (Arm B). Overall, 115 subjects received at least a total number of 50 exposure days (EDs) in Arm A and 17 subjects completed at least 25 EDs of routine prophylaxis in Arm B. Routine prophylaxis resulted in a mean ABR (95% CI) of 0.7 (0.5, 1.0), a median (Q1, Q3) ABR of 0 (0, 1.0), and a median (Q1, Q3) annualized joint bleeding rate of 0 (0, 1.0). An intra-subject comparison (n = 78) between mean ABR during on-study prophylaxis with Altuviiio and that during pre-study FVIII prophylaxis yielded a 77%
Three multi-center, open-label, non-controlled trials (n = 213) were conducted to evaluate the safety and efficacy of adult adults with severe hemophilia A. Additionally, efficacy results supported the potential for rFVIIIFc dosing 1 to 2 times per week efficacious in the prevention and treatment of bleeding events, including within the setting of major surgery, in adolescents and antihemophilic factor (recombinant) [Novoeight] in the control and prevention of breakthrough bleeds, routine prophylaxis and perioperative management in previously treated patients with hemophilia A.32 Of the 213 patients included, 150 patients were approach for prophylactic dosing over the other cannot be determined. Authors concluded that rFVIIIFc was well-tolerated and weekly dosing regimens resulted in a significant reduction in ABR compared with episodic treatment, the superiority of one prophylactic regimens (arms1 and 2, respectively). Thus, although both the individualized (median twice-weekly dosing) and population and no participants developed inhibitors. The study was not designed to compare individualized and weekly prophylactic regimens (arms1 and 2, respectively). Thus, although both the individualized (median twice-weekly dosing) and weekly dosing regimens resulted in a significant reduction in ABR compared with episodic treatment, the superiority of one approach for prophylactic dosing over the other cannot be determined. Authors concluded that rFVIIIFc was well-tolerated and efficacious in the prevention and treatment of bleeding events, including within the setting of major surgery, in adolescents and adults with severe hemophilia A. Additionally, efficacy results supported the potential for rFVIIIFc dosing 1 to 2 times per week (current treatment guidelines recommend dosing 3-4 times weekly).

Mahlangu et al. conducted a multi-center, prospective, open-label, phase 3 study which evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) [Eloctate] for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥ 12 years with severe hemophilia A.37 The study participants were divided up into 3 treatment arms: arm 1, individualized prophylaxis (25-65 i.u./kg every 3-5 days, n = 118); arm 2, weekly prophylaxis (65 i.u./kg, n = 24); and arm 3, episodic treatment (10-50 i.u./kg, n = 23). A subgroup compared recombinant FVIII (rFVIII) and rFVIIIFc pharmacokinetics. Annualized bleeding rate (ABR) was the primary measured outcome; and inhibitor development and adverse events were secondary efficacy endpoints evaluated. The terminal half-life of rFVIIIFc (19.0 hours) was extended 1.5-fold vs rFVIII (12.4 hours; p < .001). Across all arms, 757 bleeding episodes were treated with rFVIIIFc during the efficacy period. Overall, 87.3% of bleeding episodes were resolved with 1 injection, and 97.8% were controlled with ≤ 2 injections. In arm 1, the median weekly dose was 77.9 i.u./kg; approximately 30% of subjects achieved a ≥ 5 - reduction in treated bleeds (95% CI: 58%, 87%). All subjects with target joints at baseline (defined as ≥ 3 spontaneous bleeding episodes in a major joint which occurred in a consecutive 6-month period) achieved resolution of all target joints (45/45, 100%) with 12 months of prophylactic treatment with Altuviiio (defined as ≤ 2 bleeding episodes in the target joint in 12 months). The efficacy of weekly 50 IU/kg Altuviiio as routine prophylaxis in children < 12 years was evaluated as estimated by the mean annualized bleed rate (ABR). At the time of the interim analysis, a total of 67 children (31 children < 6 years of age and 36 children 6 to < 12 years of age) were enrolled to receive Altuviiio for routine prophylaxis at a dose of 50 IU/kg IV once weekly for 52 weeks. In subjects with at least 26 weeks of exposure (n = 23), routine prophylaxis resulted in a mean ABR (95% CI) of 0.5 (0.2, 1.3) and a median (Q1, Q3) ABR of 0 (0, 1.3) for treated bleeds. For all bleeds (treated and non treated), the mean ABR (95% CI) was 3.6 (1.6, 8.4) and the median (Q1, Q3) ABR was 0 (0, 4.5). In the adult and adolescent study, a total of 362 bleeding episodes were treated with Altuviiio, most occurring during on-demand treatment in Arm B. Majority of bleeding episodes were localized in joints. Response to the first injection was assessed by subjects at least 8 hours after treatment. A 4-point rating scale of excellent, good, moderate, and no response was used to assess response. Bleeding was resolved with a single 50 IU/kg injection of Altuviiio in 96.7% of bleeding episodes. The median (Q1; Q3) total dose to treat a bleeding episode was 50.9 IU/kg (50.0; 51.9). Control of bleeding episodes was similar across the treatment arms. Perioperative hemostasis was assessed in 13 major surgeries in 12 subjects (11 adults and 1 child). Of the 13 major surgeries, 12 surgeries required a single pre-operative dose to maintain hemostasis during surgery; for 1 major surgery during routine prophylaxis no pre-operative loading dose was administered on the day of/ or before surgery. The median dose pre-operative injection was 49.96 IU/kg (range 12.7 - 61.9). The clinical evaluation of hemostatic response during major surgery was assessed using a 4-point scale of excellent, good, moderate, or poor/none. The hemostatic effect of Altuviiio was rated as “excellent” in 13 of 13 surgeries (100%). No surgery had an outcome rated as “poor/none” or “missing.” Types of major surgeries assessed include major orthopedic procedures such as joint arthroplasties (joint replacements of knee, hip, and elbow), joint revisions and ankle fusion. Other major surgeries included molar extractions and rhinoplasty/mentoplasty. Perioperative hemostasis was assessed in 22 minor surgeries in 19 subjects (12 adults and 7 children). The hemostatic response was evaluated by the investigator/surgeon in 15 of these minor surgeries; an excellent response was reported in all (100%).

Three multi-center, open-label, non-controlled trials (n = 213) were conducted to evaluate the safety and efficacy of anhemophilic factor (recombinant) [Novoeight] in the control and prevention of breakthrough bleeds, routine prophylaxis and perioperative management in previously treated patients with hemophilia A.32 Of the 213 patients included, 150 patients were 12 years or older and 63 patients were younger than 12 years of age. More than 80% received the 3-times-per-week regimen. Bleeding episodes were treated according to the investigator's discretion, with a target factor VIII activity level greater than 0.5 international units/mL. Bleeding episodes and perioperative management with anhemophilic factor (recombinant) were considered successfully treated if the patient (home dosing) or investigator
Patients were treated for 6 months with 20 to 40 international units/kg (mean, 32 international units/kg) every 2 to 3 days. The annualized bleeding rate for all types of bleeds was 2.39 episodes/patients (median, 0; range, 0 to 15.69) among adults. Most bleeding episodes (90.4%) were treated with 1 dose; 97.3% required 1 or 2 injections. The bleeding rates were decreased by 83% in the fixed-weekly interval group and 87% in the individualized group compared with the episodic treatment group. Most bleeding episodes (90.4%) were treated with 1 dose; 97.3% required 1 or 2 injections. The median annualized overall bleeding rates were 2.95% in the fixed-interval prophylaxis group, 1.38% in the individualized-interval prophylaxis group, and 17.69% in the episodic treatment group. Researchers concluded that rFIXFc is safe and effective for the treatment and prevention of bleeding events, including those incurred during major surgeries, in previously treated adolescents and adults.

Valentino et al. conducted an open-label, multicenter trial which compared the effectiveness of two prophylactic treatment regimens with antihemophilic factor (recombinant), plasma/albumin free method (rAHF-PFM) [Advate], as well as between on-demand and prophylaxis treatments, in preventing bleeding in hemophilia A. Thirty-six previously on-demand-treated patients aged 7-59 years with FVIII levels ≤ 2% received 6 months of on-demand treatment and were then randomized to 12 months of either standard (20-40 i.u. kg(-1) every other day) or pharmacokinetic (PK)-tailed prophylaxis (20-80 i.u. kg(-1) every third day) prophylaxis, both regimens intended to maintain FVIII trough levels at or above 1%. The primary endpoint was differences in annualized bleeding rates (ABRs) between the two prophylaxis regimens. Secondary endpoint evaluated included differences in ABRs between patients first treated on-demand and then on prophylaxis. A total of 1640 bleeding episodes occurred in 66 of 66 subjects during the on-demand period, 104 episodes occurred in 19 of 32 subjects during standard prophylaxis and 141 episodes in 25 out of 34 subjects during the PK-tailed prophylaxis. Twenty-two (33.3%) patients on prophylaxis treatment experienced no bleeding episodes, whereas none treated on-demand were free from an episode of bleeding. ABRs for the two prophylaxis regimens were comparable, however, the differences between on-demand and either prophylaxis were statistically significant (p < 0.0001): median (interquartile range [IQR]) ABRs were 43.9 (21.9), 1.0 (3.5), 2.0 (6.9) and 1.1 (4.9) during on-demand treatment, standard, PK-tailed and any prophylaxis, respectively. No differences in FVIII consumption or adverse event rates between prophylaxis regimens were noted. No patient developed FVIII inhibitors. Researchers concluded that the outcomes of this trial demonstrated comparable safety and effectiveness for two prophylaxis regimens and that prophylaxis significantly reduces bleeding compared with on-demand treatment. Additionally, PK-tailed prophylaxis offers an alternative to standard prophylaxis for the prevention of bleeding in hemophilia A.

In a single-arm study of adults and adolescents (n = 55) with hemophilia A, 84.2% of all bleeding episodes were successfully treated successfully with Wilate. Minor episodes accounted for 26.3% of all bleeding, moderate episodes for 56.1%, and major episodes for 17.5%; there were no life-threatening bleeding episodes. Only 1 dose of Wilate(R) was required in 63.2% of the bleeding episodes, 2 doses were required in 21.1% of episodes, 3 doses were required in 12.3% of episodes, and 4 or more doses were required in 3.6% of episodes. Mean Wilate dose was 34 international units/kg per dose. Successful treatment was defined as excellent, good, or moderate efficacy as assessed by the patient. Excellent efficacy was defined as abrupt pain relief and/or improvement in bleeding within 8 hours of a single dose, good efficacy was defined as definite pain relief and/or improvement in bleeding within 8 to 12 hours after dose and requiring up to 2 doses for resolution, and moderate efficacy was defined as probable or slight benefit within 12 hours of a dose and requiring more than 2 doses for resolution. The annualized bleeding rate for spontaneous bleeds in adults (n = 50) was 1.67 episodes/patient (median, 0; range, 0 to 11.76). The annualized bleeding rate for all types of bleeds was 2.39 episodes/patients (median, 0; range, 0 to 15.69) among adults. Patients were treated for 6 months with 20 to 40 international units/kg (mean, 32 international units/kg) every 2 to 3 days.

**Hemophilia B**

Powell et al conducted a phase 3, nonrandomized, open-label study which evaluated the safety, efficacy, and pharmacokinetics of coagulation factor IX Fc fusion protein recombinant (rFIXFc) [Alprolix] for prophylaxis, treatment of bleeding, and perioperative hemostasis in patients with severe factor IX deficiency (hemophilia B). Patients (age range, 12 to 71 years; n = 123) were evaluated in trials to determine hemostatic efficacy of rFIXFc for prophylaxis, treatment of bleeding, and perioperative management. In the fixed-interval prophylaxis arm, patients received an initial dose of 50 i.u./kg, which was then adjusted to maintain a factor IX trough level of at least 1% to 3% above baseline (median dose, 45.2 i.u./kg). Patients in the individualized-interval arm received rFIXFc 100 i.u./kg every 10 days, with the interval adjusted to maintain a factor IX trough of at least 1% to 3% above baseline (median dosing interval, 12.5 days). Patients in the episodic treatment arm received rFIXFc 20 to 100 i.u./kg as needed for bleeding. The primary efficacy endpoint was the annualized bleeding rate, and safety endpoints included the development of inhibitors and adverse events. A total of 636 bleeding episodes were assessed in 114 patients, who received a median total dose of 46.99 i.u. per bleeding episode. During a median follow-up of 51.4 weeks, the annualized bleeding rates were decreased by 83% in the fixed-weekly interval group and 87% in the individualized group compared with the episodic treatment group. Most bleeding episodes (90.4%) were treated with 1 dose; 97.3% required 1 or 2 injections. The median annualized overall bleeding rates were 2.95% in the fixed-interval prophylaxis group, 1.38% in the individualized-interval prophylaxis group, and 17.69% in the episodic treatment group. Researchers concluded that rFIXFc is safe and effective for the treatment and prevention of bleeding events, including those incurred during major surgeries, in previously treated adolescents.
and adults with hemophilia B. Fc fusion did not impair factor IX activity or result in increased immunogenicity. The prolonged half-life of rFIXFc allowed for effective prophylaxis, with injections every 1 to 2 weeks. Additionally, the potential for higher trough levels of rFIXFc or longer intervals between doses may lead to greater use of prophylaxis among patients with hemophilia B.

In a prospective, open-label, uncontrolled trial, efficacy of routine prophylaxis with coagulation factor IX [Rixubis] in adult patients with hemophilia B (n = 56) was evaluated. Primary endpoint was reduction in frequency of bleeding episodes. Patients received coagulation factor IX recombinant 40 to 60 international units/kg IV twice weekly for 3 months or longer. At screening, all patients had severe (factor IX level < 1%) or moderately severe (factor IX level ≤ 2%) hemophilia B, with 12 or more documented bleeding episodes requiring treatment within 12 months prior to enrollment. After a mean duration of 6 months of treatment with coagulation factor IX recombinant at a mean twice-weekly dose of 49.4 international units/kg/infusion, the mean total annualized bleeding rate was 4.3 for all bleeds, 1.7 for spontaneous bleeds, and 2.9 for joint bleeds compared with 33.9 +/- 17.37 mean total annualized bleeding rate in the on-demand arm (n = 14) during the mean 3.5-month period.30

Two studies were conducted to provide coagulation factor IX (human) [Mononine] for treatment of hemophilia B subjects who required extensive Factor IX replacement for surgery, trauma, or spontaneous bleeding (73 unique subjects and eight subjects enrolled twice for a total of 81 subjects), as well as to evaluate the safety and efficacy of coagulation factor IX (human) treatment.15 The overall mean recovery during treatment was determined to be 1.23 ±0.42 i.u./dL rise/i.u./kg (K) (range = 0.59 to 2.92 K) among the 55 subjects included in recovery analyses in Study 1 and to be 1.12 ±0.52 K (range = 0.61 to 2.08 K) among 10 subjects included in these analyses in Study 2. Five (5/81,6%) subjects reported adverse events attributed to coagulation factor IX (human) across both studies. In these studies, 100 doses of coagulation factor IX (human) were administered at a range of 71 to 161 i.u./kg to a total of 36 subjects. Sixty-seven of these infusions were the subject of recovery analyses. Mean recovery tended to decrease as the dose of coagulation factor IX (human) increased:1.09 ±0.52 K at doses > 75-95 i.u./kg (n = 38), 0.98 ±0.45 K at doses > 95-115 i.u./kg (n = 21), 0.70 ±0.38 K at doses > 115-135 i.u./kg (n = 2), 0.67 K at doses > 135-155 i.u./kg (n = 1), and 0.73 ±0.34 K at doses > 155 i.u./kg (n = 5). Among the 36 subjects who received these high doses, only one (2.8%) reported an adverse experience with a possible relationship to coagulation factor IX (human). No thrombogenic complications were observed or reported.

**Technology Assessments**

As an update to the 2011 intervention review, the Cochrane Collaboration published a 2015 review which evaluated the effectiveness of recombinant Factor VIIa (containing no human proteins) as compared to concentrates derived from plasma for treating acute bleeding episodes in people with hemophilia with inhibitors. Researchers again concluded that although there is a need for further randomized controlled trials, both rFVIIa (NovoSeven®) and aPCC (FEIBA®) are similar in efficacy and safety. Additionally, the review suggested that researchers in the field define commonly agreed objective measures in order to enable the pooling of their results, thus increasing the power of comparisons. 21, 47

The Cochrane Collaboration also published an intervention review which evaluated the effectiveness of clotting factor concentrate prophylaxis in the management of people with hemophilia A or B in 2011.22 Authors conclude that there is strong evidence from randomized controlled trials and observational trials that prophylaxis started early preserves joint function in children with hemophilia as compared to on-demand treatment. This effect is due to a consistent reduction in total bleeds and hemarthrosis and leads to a significant improvement in quality of life, however, treatment prophylaxis is linked to an increased factor usage and overall cost of therapy. There was insufficient evidence to show that treatment prophylaxis decreased bleeding and related complications in patients with existing joint damage. Randomized controlled trials are warranted to establish the best preventative regimen for these patients.

**Professional Societies**

In March 2020, the National Hemophilia Foundation (NHF) released updated hemophilia treatment guidelines entitled Medical and Scientific Advisory Council (MASAC) Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders #259.48,50 Updates to these recommendations were released in MASAC Document 272 in April 2022.59 A summary of the NHF recommendations for physicians treating patients with hemophilia A and B, von Willebrand Disease, and other congenital bleeding disorders are as follows:
### Treatment of Patients with Hemophilia A

<table>
<thead>
<tr>
<th>Recombinant Factor VIII Concentrates</th>
<th>Advate</th>
<th>Treatment of choice in hemophilia A.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helixate FS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kogenate FS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kovaltry</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NovoEight</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nuwiq</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xyntha</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prolonged Half-Life Recombinant Factor VIII Concentrate</td>
<td>Adynovate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Afstyla</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eloctate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Esperoct</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jivi</td>
<td></td>
</tr>
<tr>
<td>Plasma-Derived Factor VIII Concentrates</td>
<td>Hemofil M</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>Alphanate</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>Humate-P</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>Koate-DVI</td>
<td></td>
</tr>
<tr>
<td>Humanized bispecific FIXa- and FX- directed monoclonal antibody</td>
<td>Hemlibra</td>
<td>Recommended</td>
</tr>
<tr>
<td>Cryoprecipitate</td>
<td>Cryoprecipitate</td>
<td>Not recommended except in life- and limb-threatening emergencies when no factor VIII concentrate is available.</td>
</tr>
<tr>
<td>Desmopressin</td>
<td>DDAVP Injection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stimate Nasal Spray for Bleeding</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Patients with Hemophilia B

<table>
<thead>
<tr>
<th>Recombinant Factor IX Concentrate</th>
<th>BeneFIX</th>
<th>Treatment of choice in hemophilia B.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ixinity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rixubis</td>
<td></td>
</tr>
<tr>
<td>Prolonged Half-Life Recombinant Factor IX Concentrate</td>
<td>Alprolix</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Idelvion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rebinyn</td>
<td></td>
</tr>
<tr>
<td>Plasma-Derived Factor IX Concentrates</td>
<td>AlphaNine SD</td>
<td>Recommended</td>
</tr>
<tr>
<td></td>
<td>Mononine</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Patients with von Willebrand Disease (VWD)

<table>
<thead>
<tr>
<th>Desmopressin</th>
<th>DDAVP Injection</th>
<th>Recommended for most persons with VWD Type 1. Some Type 2A patients may respond to DDAVP, however clinical testing should be done to determine whether DDAVP can be used. Do not use in children &lt; 2 years of age. Use with caution in pregnant women during labor and delivery.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stimate Nasal Spray for Bleeding</td>
<td></td>
</tr>
</tbody>
</table>
### Treatment of Patients with von Willebrand Disease (VWD)

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant von Willebrand Factor Concentrate</td>
<td>Vonvendi</td>
<td>Treatment of choice in von Willebrand disease. May be used to treat patients with type 2B and type 3 VWD; it can also be used in patients with types 1, 2A, 2M, and 2N VWD who are not responsive to DDAVP and in children &lt; 2 years of age regardless of VWD type.</td>
</tr>
<tr>
<td>Plasma-Derived Factor VIII / von Willebrand Factor</td>
<td>Alphanate</td>
<td>Recommended in certain types of vWD that do not respond to DDAVP (i.e. Type 2B VWD and Type 3 VWD), and for use in Type 1 or 2A VWD patients who have become transiently unresponsive to DDAVP and in surgical situations, especially in young under the age of 2 years. In certain patients, Koate-DVI may also be effective.</td>
</tr>
<tr>
<td>Humate-P</td>
<td>Wilate</td>
<td>Not recommended except in life- and limb-threatening emergencies when VWD-containing factor VIII concentrate is not immediately available.</td>
</tr>
<tr>
<td>Cryoprecipitate</td>
<td>Cryoprecipitate</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Patients with Factor VII Deficiency

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Factor VIIa Concentrate</td>
<td>NovoSeven RT</td>
<td>Recommended</td>
</tr>
</tbody>
</table>

### Treatment of Patients with Inherited Hemophilia A and Inhibitors to Factor VIII

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humanized bispecific Fixa- and FX- directed monoclonal antibody</td>
<td>Hemlibra</td>
<td>Recommended</td>
</tr>
</tbody>
</table>

### Treatment of Patients with Inherited Hemophilia A or B and Inhibitors to Factor VIII or Factor IX

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Derived Activated Prothrombin Complex Concentrate (aPCC)</td>
<td>FEIBA</td>
<td>Recommended, however, products are not interchangeable. Choice of product depends on multiple factors, including type of inhibitor (low- or high-responding), current titer of inhibitor, location of the bleed, and previous response to these products. For high-titer inhibitors, immune tolerance induction is the best option for inhibitor eradication. Do not exceed recommended doses to reduce the risk of thrombosis.</td>
</tr>
<tr>
<td>Recombinant Factor VIIa Concentrate</td>
<td>NovoSeven RT</td>
<td></td>
</tr>
<tr>
<td>Sevenfact</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Patients with Acquired Inhibitors to Factor VIII

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Factor VIIa Concentrate</td>
<td>NovoSeven RT</td>
<td>Recommended</td>
</tr>
<tr>
<td>Recombinant Porcine Factor VIII Concentrate</td>
<td>Obizur</td>
<td></td>
</tr>
</tbody>
</table>

### Treatment of Patients with Factor XIII Deficiency

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Derived Factor XIII Concentrate</td>
<td>Corifact</td>
<td>Recommended</td>
</tr>
</tbody>
</table>

### Treatment of Patients with Factor XIII-A Subunit Deficiency

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Derived Factor XIII-A Subunit Concentrate</td>
<td>Tretten</td>
<td>Recommended. It is not effective in those patients that lack FXIII-B subunit.</td>
</tr>
</tbody>
</table>

### Treatment of Patients with Factor II or Factor X Deficiencies

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Derived Prothrombin Complex Concentrates (pd-PCCs)</td>
<td>Profilnine</td>
<td>Recommended to treat patients with deficiencies of factors II and X. However, it should be noted that the content of these factors varies from lot to lot and product to product. Note the relative content of factors Profilnine (II &gt; IX = X &gt; VII).</td>
</tr>
</tbody>
</table>

### Treatment of Patients with Factor I Deficiency

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Trade Name</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma-Derived Fibrinogen Concentrate</td>
<td>RiaSTAP</td>
<td>Recommended for treatment of congenital hypofibrinogenemia and afibrinogenemia but not dysfibrinogenemia.</td>
</tr>
<tr>
<td>Fibryga</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Treatment of Patients with Factor I Deficiency

| Cryoprecipitate | Cryoprecipitate | The only currently available product for dysfibrinogenemia. Not recommended in patients with afibrinogenemia except in life- and limb-threatening emergencies when fibrinogen concentrate is not immediately available. |

### Treatment of Patients with Factor X Deficiencies

| Plasma-Derived Factor X Concentrate | Coagadex | Recommended |

The World Federation of Hemophilia developed 2020 guidelines which provides practical guidelines on the general management of hemophilia which is summarized below:\(^{57}\)

- For patients with hemophilia, the WFH does not express a preference for recombinant over plasma-derived clotting factor concentrates.
- For treatment of FIX deficiency in patients with hemophilia B, the WFH recommends a product containing only FIX rather than prothrombin complex concentrates (PCCs), which also contain other clotting factors, such as factors II, VII, and X, some of which may become activated during manufacture and may predispose the patient to thromboembolism.
- Pure FIX concentrates are recommended over prothrombin complex concentrates for hemophilia B patients requiring prolonged therapy at high doses, undergoing surgery, liver disease, previous thrombosis or known thrombotic tendency, or concomitantly using drugs known to have thrombogenic potential.
- For patients with hemophilia A or B, there is no evidence for any clinical safety issues in persons with hemophilia to recommend a preference among the various mechanisms of action (e.g., PEGylation, Fc-fusion, albumin-fusion) used to extend the half-life of clotting factor concentrates.
- For people with hemophilia A with an inhibitor requiring treatment for acute bleeding complications or surgery, the WFH recommends that a bypassing agent be used.
- For patients with hemophilia B and an inhibitor with a history of anaphylaxis to FIX-containing clotting factor concentrates, recombinant activated factor VIIa must be administered as activated prothrombin complex concentrate cannot be used.
- The WFH recommends that patients with hemophilia with an inhibitor should be considered for regular prophylaxis to prevent bleeding events.
- For patients with hemophilia, the WFH strongly recommends the use of viral-inactivated plasma-derived or recombinant clotting factor concentrates in preference to cryoprecipitate or fresh frozen plasma which are not recommended due to concerns about the safety and quality.
- For patients with mild or moderate hemophilia A and carriers of hemophilia A, the WFH recommends considering desmopressin (DDAVP) as an option for treatment.
- For adults, the WFH recommends DDAVP not be used for more than 3 consecutive days and only under close supervision. If DDAVP is administered twice in a single day, subsequent daily dosing should be limited to once per day.
- For children under 2 years of age, the WFH alerts that DDAVP is contraindicated due to increased risk of seizures as consequences of water retention and hyponatremia.
- For patients at risk of cardiovascular disease or thrombosis, the WFH recommends that DDAVP should be used with caution due to the risk of thromboembolism and myocardial infarction.
- For patients with hemophilia, the WFH recommends that antifibrinolytics are a valuable alternative to use alone or as adjuvant treatment, particularly in controlling mucocutaneous bleeding (e.g., epistaxis, oral and gastrointestinal bleeding, and menorrhagia) and for dental surgery and eruption or shedding of teeth.
- For patients with hematuria, the WFH recommends against the use of antifibrinolytics, as it is contraindicated in these patients due to increased risk of obstructive uropathy.
- For patients with renal impairment, the WFH recommends reduced dosing of antifibrinolytics and close monitoring.
- For patients with hemophilia A or B with a severe phenotype (note that this may include patients with moderate hemophilia with a severe phenotype), the WFH strongly recommends that such patients be on prophylaxis sufficient to prevent bleeds at all times, but that prophylaxis should be individualized, taking into consideration patient bleeding phenotype, joint 82 WFH Guidelines for the Management of Hemophilia, 3rd edition status, individual pharmacokinetics, and patient self-assessment and preference.
- For pediatric patients with severe hemophilia A or B, the WFH recommends early initiation of prophylaxis with clotting factor concentrates (standard or extended half-life FVIII/FIX) or other hemostatic agent(s) prior to the onset of joint disease and ideally before age 3, in order to prevent spontaneous and break-through bleeding including hemarthroses which can lead to joint disease.
For adolescents and adults with hemophilia who show evidence of joint damage and have not as yet been on prophylaxis, the WFH recommends commencing tertiary prophylaxis in order to reduce the number of hemarthroses, spontaneous and break-through bleeding, and slow down the progression of hemophilic arthropathy.

For patients with severe phenotype hemophilia A or B on prophylaxis, the WFH recommends that patients/ caregivers be taught to maintain timely and accurate records of bleeding episodes and treatment and be followed in hemophilia treatment centers.

For patients with newly diagnosed hemophilia A and B, the WFH recommends regular inhibitor screening at least every 6-12 months, and then annually.

For patients with hemophilia A and B who receive clotting factor concentrate for more than 5 consecutive days, the WFH suggests inhibitor screening within 4 weeks of the last infusion and for those patients who have poor or no response to adequate clotting factor replacement therapy, or who have lower than expected factor recovery or half-life.

For patients with hemophilia A and FVIII inhibitors who develop an acute bleed, the WFH recommends that treatment be based on whether the inhibitor is low-responding or high-responding.

For patients with hemophilia A and inhibitors who have acute bleeds, the WFH recommends FVIII concentrate for those with low-responding inhibitors, and a bypassing agent (recombinant factor VIIIa [rFVIIa] or activated prothrombin complex concentrate [aPCC]) for those with high-responding inhibitors.

For patients with hemophilia A and high-responding FVIII inhibitors who undergo surgery or an invasive procedure, the WFH recommends bypass agent therapy (rFVIIa or aPCC) at the discretion of the clinician. If single-agent bypass fails, sequential bypass agent treatment, i.e., rFVIIa alternating with aPCC, is another therapeutic approach. The WFH also recommends close clinical monitoring for thrombosis.

For patients with hemophilia B and inhibitors who develop an acute bleed, the WFH recommends treatment based on whether the inhibitor is low-responding or high-responding and whether there is a history of allergic reactions.

For patients with hemophilia B and low-responding FIX inhibitors, the WFH recommends use of a FIX containing product to treat acute bleeds, as long as there is no allergic reaction to FIX.

For patients with hemophilia B and high-responding FIX inhibitors, the WFH prefers rFVIIa over aPCC to treat acute bleeds, as aPCC contains FIX and may cause or worsen an allergic reaction.

For patients with hemophilia B and low-responding FIX inhibitors who undergo surgery, the WFH has no preference for type of FIX products, but recommends more frequent dosing due to the short FIX half-life.

For patients with hemophilia B and FIX inhibitors who undergo surgery, the WFH recommends rFVIIa over aPCC, as aPCC contains FIX and may cause or worsen an allergic reaction.

For patients with hemophilia A or B who switch to another type or brand of factor product, the WFH has no preference in the choice of specific type of therapy, as current evidence indicates product switching does not increase the risk of inhibitor development, but rigorous controlled trials are lacking.

The British Committee for Standards in Haematology released updated inhibitor treatment guidelines in 2013 entitled, “Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia.” A summary of the recommendations for the management of inhibitors is outlined below. Designations for the quality of evidence (A – highest, C – lowest) and strength of recommendation (1 – strong, 2 – weak) are given at the end of each recommendation.

- **Bleeds** may be managed with large doses of FVIII/IX in low responders and FVIII inhibitor bypassing activity (FEIBA) or activated recombinant FVII (rFVIIa) in high responders. FVIII can be considered for major bleeds in high responding patients with low-titre antibodies. For low-responding patients with low-titre inhibitors it is better to increase the frequency of FVIII/FIX infusions rather than increase the dose (2C).

- **Bleeds** may be managed with large doses of FVIII/IX in low responders and FVIII inhibitor bypassing activity (FEIBA) or activated recombinant FVII (rFVIIa) in high responders. FVIII can be considered for major bleeds in high responding patients with low-titre antibodies. For low-responding patients with low-titre inhibitors it is better to increase the frequency of FVIII/FIX infusions rather than increase the dose (2C).

- **Patients** who have experienced allergic reactions to FIX should be treated with rFVIIa (1C).

- **Single dose FEIBA** (50-100 µg/kg), single high dose (270 µg/kg) rFVIIa or 1-3 standard doses (90 µg/kg) of rFVIIa are all treatment options for early haemarthroses (1B).

- **Treatment of non-joint bleeds** should be with FVIII/FIX or standard doses of FEIBA or rFVIIa until further data are available (2C).

- **Tranexamic acid** should be considered in all patients who are not receiving high doses of FEIBA (> 200 iu/kg/d) but is especially important for mucosal bleeds (2C).

- **Some bleeds**, unresponsive to bypassing agents, may be successfully treated by removal of the inhibitor using plasmaphaeresis and immunoadsorption together with high dose FVIII/IX concentrate (2B).
Combined treatment with rFVIIa and FEIBA should only be considered for life- or limb-threatening bleeds unresponsive to either agent used alone (2C).

The guidelines also address recommendations for the prophylaxis for inhibitor patients:
- Prophylaxis with a bypassing agent should be considered in young children after the first haemarthrosis to reduce the risk of arthropathy (2C).
- If prophylaxis is required in patients awaiting ITI, rFVIIa should be used (2C).
- Prophylaxis with bypassing agents in patients on ITI should undergo a trial reduction when FVIII recovery is measurable and stopped when the Bethesda titre is negative, assuming significant break-through bleeds do not result (2C).
- Prophylaxis may be considered in older patients with recurrent bleeds or progressive arthropathy (2C).
- The choice of product for prophylaxis should be considered on an individual basis, taking into account previous response to treatment, logistics of administration and cost (2C).
- If the initial regimen is unsuccessful, increasing the frequency of infusion is more likely to be effective than increasing the dose (2C).

The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) released an updated guidelines entitled 2021 Guidelines on the Management of von Willebrand Disease (VWD). A summary of the recommendations for the management of VWD is as follows:
- In patients with VWD with a history of severe and frequent bleeds, the guideline panel suggests using long-term prophylaxis rather than no prophylaxis.
- In patients for whom desmopressin is a valid treatment option (primarily type 1 VWD) and who have a baseline VWF level of < 0.30 IU/mL, the panel suggests performing a trial of desmopressin and treating based on the results over not performing a trial and treating with tranexamic acid or factor concentrate.
- In these patients, the pane suggests against treating with desmopressin in the absence of desmopressin trial results.
- In patients with VWD and cardiovascular disease who require treatment with antiplatelet agents or anticoagulant therapy, the panel suggests giving the necessary antiplatelet or anticoagulant therapy over no treatment.
- The panel suggests targeting both FVIII and VWF activity levels of ≥ 0.50 IU/mL for at least 3 days after surgery.
- The panel suggests against using only FVIII ≥ 0.50 IU/mL as a target level for at least 3 days after surgery.
- In patients undergoing minor surgery or minor invasive procedures, the panel suggests increasing VWF activity levels to ≥ 0.50 IU/mL with desmopressin or factor concentrate with the addition of tranexamic acid over raising VWF levels to ≥ 0.50 IU/mL with desmopressin or factor concentrate alone.
- The panel suggests giving tranexamic acid alone over increasing VWF activity levels to ≥ 0.50 IU/mL with any intervention in patients with type 1 VWD with baseline VWF activity levels of > 0.30 IU/mL and a mild bleeding phenotype undergoing minor mucosal procedures.
- The panel suggests using either hormonal therapy (combined hormonal contraception [CHC] or levonorgestrel-releasing intrauterine system) or tranexamic acid over desmopressin to treat women with VWD with heavy menstrual bleeding who do not wish to conceive.
- The panel suggests using tranexamic acid over desmopressin to treat women with VWD and heavy menstrual bleeding who wish to conceive.
- In women with VWD for whom neuraxial anesthesia during labor is deemed suitable, the panel suggests targeting a VWF activity level of 0.50 to 1.50 IU/mL over targeting an activity level of > 1.50 IU/mL to allow neuraxial anesthesia.
- The guideline panel suggests the use of tranexamic acid over not using it in women with type 1 VWD or low VWF levels (and this may also apply to types 2 and 3 VWD) during the postpartum period.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Advate (antihemophilic factor (recombinant)) is approved by the U.S. Food and Drug Administration (FDA) for use in children and adults with hemophilia A for the following: control and prevention of bleeding episodes; perioperative management; and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Advate is not indicated for the treatment of von Willebrand disease.
Adynovate (antihemophilic factor (recombinant), PEGylated) is FDA-labeled in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency) for the following: on-demand treatment and control of bleeding episodes; perioperative management; and routine prophylaxis to reduce the frequency of bleeding episodes. Adynovate is not indicated for the treatment of von Willebrand disease.44

Afstyla (antihemophilic factor (recombinant)) is FDA-labeled in adults and children with hemophilia A (congenital Factor VIII deficiency) for the following: on-demand treatment and control of bleeding episodes; routine prophylaxis to reduce the frequency of bleeding episodes; and perioperative management of bleeding. Afstyla is not indicated for the treatment of von Willebrand disease.42

Alphanate (antihemophilic factor/von Willebrand factor complex (human)) is FDA-labeled for control and prevention of bleeding in adult and pediatric patients with hemophilia A. It is also approved for surgical and/or invasive procedures in adult and pediatric patients with von Willebrand Disease in whom desmopressin (DDAVP) is either ineffective or contraindicated. Alphanate is not indicated for patients with severe VWD (Type 3) undergoing major surgery.2

AlphaNine SD (coagulation factor IX (human)) is FDA-labeled for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B. AlphaNine SD contains low, non-therapeutic levels of Factors II, VII, and X, and, therefore, is not indicated for the treatment of Factor II, VII or X deficiencies. This product is also not indicated for the reversal of coumarin anticoagulant-induced hemorrhage, nor in the treatment of hemophilia A patients with inhibitors to Factor VIII.14

Alprolix (coagulation factor IX (recombinant), Fc fusion protein) is FDA-labeled in adults and children with hemophilia B for the following: on demand treatment and control of bleeding episodes; perioperative management of bleeding; and for routine prophylaxis to reduce the frequency of bleeding episodes. Alprolix is not indicated for induction of immune tolerance in patients with hemophilia B.34

Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for the following: routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment & control of bleeding episodes; and perioperative management of bleeding. Altuviiio is not indicated for the treatment of von Willebrand disease.60

BeneFIX (coagulation factor IX (recombinant)) is FDA-labeled for both control and prevention of bleeding episodes in adult and pediatric patients with hemophilia B, and for peri-operative management in adult and pediatric patients with hemophilia B. BeneFIX is not indicated for Induction of immune tolerance in patients with hemophilia B.17

Coagadex (coagulation factor X (human)) is FDA-labeled in adults and children with hereditary Factor X deficiency for the following: routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment, and control of bleeding episodes; and perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency.45

Corifact (factor XIII concentrate (human)) is FDA-labeled in adult and pediatric patients with congenital Factor XIII deficiency for the following: routine prophylactic treatment and peri-operative management of surgical bleeding.1

Eloctate (antihemophilic factor (recombinant), Fc fusion protein) is FDA-labeled in adults and children with hemophilia A for the following: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes. Eloctate is not indicated for the treatment of von Willebrand disease.36

Esperoct (antihemophilic factor (recombinant), glycopegylated-exei) is a coagulation Factor VIII concentrate indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct is not indicated for the treatment of von Willebrand disease.35

FEIBA (anti-inhibitor coagulant complex) is FDA-labeled in hemophilia A and B patients with inhibitors for the following: control and prevention of bleeding episodes; peri-operative management; and routine prophylaxis to prevent or reduce the frequency
of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to factor VIII or factor IX.\textsuperscript{13}

Fibryga is a human fibrinogen concentrate indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Fibryga is not indicated for dysfibrinogenemia.\textsuperscript{19}

Helixate FS (antihemophilic factor (recombinant)) is FDA-labeled for the following: control and prevention of bleeding episodes in adults and children with hemophilia A; peri-operative management in adults and children with hemophilia A; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage; and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. Helixate FS is not indicated for the treatment of von Willebrand disease.\textsuperscript{9}

Hemlibra (emicizumab-kxwh) is a bispecific factor IXa- and factor X-directed antibody and is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.\textsuperscript{51}

Hemofil M (antihemophilic factor (human)) is FDA-labeled for the prevention and control of hemorrhagic episodes in hemophilia A. Hemofil M is not indicated in von Willebrand disease.\textsuperscript{5}

Humate-P (antihemophilic factor/von Willebrand factor complex (human)) is FDA-labeled for treatment and prevention of bleeding in adults with hemophilia A. It is also indicated in adults and children with von Willebrand disease (VWD) for treatment of spontaneous and trauma-induced bleeding episodes, and for prevention of excessive bleeding during and after surgery. This includes patients with severe VWD as well as patients with mild to moderate VWD where the use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes in VWD.\textsuperscript{3}

Idelvion (coagulation factor IX (recombinant), albumin fusion protein) is FDA-labeled in children and adults with hemophilia B (congenital Factor IX deficiency) for the following: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. Idelvion is not indicated for immune tolerance induction in patients with hemophilia B.\textsuperscript{43}

IXINITY (coagulation factor IX (recombinant)) is FDA-labeled for on-demand treatment and control of bleeding episodes and perioperative management in adults and children ≥ 12 years of age with hemophilia B. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children ≥ 12 years of age with hemophilia B. IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.\textsuperscript{39}

Jivi (antihemophilic factor (recombinant), PEGylated-ahucl) is FDA-labeled for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.\textsuperscript{52}

Koâte-DVI (antihemophilic factor (human)) is FDA-labeled for the treatment of hemophilia A in which there is a demonstrated deficiency of activity of the plasma clotting factor, Factor VIII, to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia. Koâte-DVI is not approved for the treatment of von Willebrand’s disease.\textsuperscript{7}

Kogenate FS (antihemophilic factor (recombinant)) is FDA-labeled for the following: on-demand treatment and control of bleeding episodes in adults and children with hemophilia A; peri-operative management in adults and children with hemophilia A; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without preexisting joint damage; and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. Kogenate FS is not indicated for the treatment of von Willebrand disease.\textsuperscript{10}

Kovaltry (antihemophilic factor (recombinant)) is FDA-labeled in adults and children with hemophilia A (congenital Factor VIII deficiency) for the following: on-demand treatment and control of bleeding episodes; perioperative management of bleeding;
and routine prophylaxis to reduce the frequency of bleeding episodes. Kovaltry is not indicated for the treatment of von Willebrand disease.30

Mononine (coagulation factor IX (human)) is FDA-labeled for the prevention and control of bleeding in Factor IX deficiency, also known as hemophilia B or Christmas disease. It is not indicated in the treatment or prophylaxis of hemophilia A patients with inhibitors to Factor VIII. Mononine is not indicated for replacement therapy of clotting Factors II, VII and X. It is also not indicated in the treatment or reversal of coumarin-induced anticoagulation or in a hemorrhagic state caused by hepatitis-induced lack of production of liver dependent coagulation factors.15

Novoeight (antihemophilic factor (recombinant)) is FDA-labeled for the control and prevention of bleeding episodes in adults and children with hemophilia A. It is also indicated for peri-operative management and routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A. Novoeight is not indicated for the treatment of von Willebrand disease.32

NovoSeven RT (coagulation factor VIIa (recombinant)) is FDA-labeled for the following: treatment of bleeding episodes in adults and children with hemophilia A or B with inhibitors and in adults with acquired hemophilia; perioperative management in adults and children with hemophilia A or B with inhibitors and in adults with acquired hemophilia; treatment of bleeding episodes and perioperative management in congenital Factor VII (FVII) deficiency; and treatment of Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.5

Nuwiq (antihemophilic factor (recombinant)) is FDA-labeled in adults and children with hemophilia A for the following: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes. Nuwiq is not indicated for the treatment of von Willebrand disease.41

Obizur (antihemophilic factor (recombinant), porcine sequence) is FDA-labeled for the treatment of bleeding episodes in adults with acquired hemophilia A. Safety and efficacy of Obizur has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer of greater than 20 BU. Obizur is not indicated for the treatment of congenital hemophilia A or von Willebrand disease.38

Profilnine SD (factor IX complex) is FDA-labeled for the prevention and control of bleeding in patients with Factor IX deficiency due to hemophilia B. It is not indicated for use in the treatment of Factor VII deficiency.16

Rebinyn (coagulation factor IX (recombinant), GlycoPEGylated) is FDA-labeled for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Rebinyn is not indicated for immune tolerance induction in patients with hemophilia B.54

Recombinate (antihemophilic factor (recombinant)) is FDA-labeled for use in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. It is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). Recombinate is not indicated in von Willebrand’s disease.11

RiaSTAP (fibrinogen concentrate (human) is FDA-labeled for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. RiaSTAP is not indicated for dysfibrinogenemia.29

Rixubis (coagulation factor IX (recombinant)) is FDA-labeled for the following: treatment and control of bleeding episodes in adults and children with hemophilia B, peri-operative management of bleeding in adults and children with hemophilia B, and routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B. Rixubis is not indicated for induction of immune tolerance in patients with hemophilia B.30

Sevenfact [coagulation factor VIIa (recombinant)-jncw] is a coagulation factor VIIa concentrate indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of use: Sevenfact is not indicated for treatment of congenital factor VII deficiency.56
Tretten (coagulation factor XIII A-Subunit (recombinant)) is FDA-labeled for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. It is not indicated for use in patients with congenital factor XIII B-subunit deficiency.33

Vonvendi (von Willebrand factor (recombinant)) is FDA-labeled for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy in adults diagnosed with von Willebrand disease.46

Wilate (von Willebrand factor/coagulation factor VIII complex human)) is FDA-labeled in children and adults with von Willebrand disease for the following: on-demand treatment and control of bleeding episodes and perioperative management of bleeding. Wilate is indicated in adolescents and adults with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes and on-demand treatment and control of bleeding episodes.4

Xyntha, Xyntha Solofuse (antihemophilic factor [recombinant], plasma/albumin-free) is FDA-labeled for treatment and control of bleeding episodes for perioperative management and for routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A. Xyntha is not indicated in patients with von Willebrand disease.12,31

References


59. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document #272, April 27, 2022.

Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
</table>
| 10/01/2023 | **Coverage Rationale**  
- Removed reference link to the Medical Benefit Drug Policy titled *Review at Launch for New to Market Medications* for Altuviiio [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehlt]  
**Applicable Codes**  
- Updated list of applicable HCPCS codes to reflect quarterly edits; replaced C9399, J3590, and J3490 with J7214  
**Supporting Information**  
- Updated *FDA* and *References* sections to reflect the most current information  
- Archived previous policy version 2023D0047AF |

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the InterQual™ criteria, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.